Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
TTNP logo TTNP
Upturn stock ratingUpturn stock rating
TTNP logo

Titan Pharmaceuticals Inc (TTNP)

Upturn stock ratingUpturn stock rating
$4.85
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: TTNP (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $7

1 Year Target Price $7

Analysts Price Target For last 52 week
$7 Target price
52w Low $3.03
Current$4.85
52w High $14.8

Analysis of Past Performance

Type Stock
Historic Profit -63.24%
Avg. Invested days 15
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 6.56M USD
Price to earnings Ratio -
1Y Target Price 7
Price to earnings Ratio -
1Y Target Price 7
Volume (30-day avg) 1
Beta 1.3
52 Weeks Range 3.03 - 14.80
Updated Date 08/15/2025
52 Weeks Range 3.03 - 14.80
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -4.61

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -57.2%
Return on Equity (TTM) -105.7%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 326634
Price to Sales(TTM) 3440.44
Enterprise Value 326634
Price to Sales(TTM) 3440.44
Enterprise Value to Revenue 7.04
Enterprise Value to EBITDA -0.92
Shares Outstanding 1330230
Shares Floating 521698
Shares Outstanding 1330230
Shares Floating 521698
Percent Insiders 49.68
Percent Institutions 2.04

ai summary icon Upturn AI SWOT

Titan Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

Titan Pharmaceuticals, Inc. was founded in 1992. It is focused on the development and commercialization of proprietary therapeutics utilizing its ProNeurau00ae long-acting delivery system. Early development focused on treatments for hypothyroidism, but its focus shifted to opioid addiction with Probuphineu00ae.

business area logo Core Business Areas

  • Segment Name: Pharmaceuticals: Develops and commercializes pharmaceutical products utilizing ProNeurau00ae, with a primary focus on addiction treatment. Their main area is developing products that are based on long-acting formulations.

leadership logo Leadership and Structure

The leadership team is headed by a CEO and other key executives responsible for various functions such as research, development, and commercialization. The structure includes departments for clinical development, regulatory affairs, and commercial operations.

Top Products and Market Share

overview logo Key Offerings

  • Product Name: Probuphine: Probuphine is a subdermal implant for the maintenance treatment of opioid use disorder in patients who are stable on low-to-moderate doses of buprenorphine. Market share data is not readily available publicly. Competitors include generic buprenorphine products (pills and sublingual films from companies like Mylan, Teva) and other long-acting buprenorphine formulations like Sublocade (Indivior).

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry, particularly the segment focused on addiction treatment, is characterized by high regulatory hurdles, intense competition, and a significant unmet need for effective therapies. Increasing awareness of the opioid crisis drives demand.

Positioning

Titan Pharmaceuticals is positioned as a developer of long-acting, implantable drug delivery systems for chronic diseases, especially addiction. Their advantage lies in the ProNeura technology. Titan's competitors are other pharmaceutical companies in the addiction treatment space, including those with generic medications and injectable products.

Total Addressable Market (TAM)

The opioid addiction treatment market is estimated to be worth billions of dollars annually. Titan's position relies on the adoption of long-acting treatments and their ability to capture a portion of the buprenorphine maintenance market. Specific TAM estimates vary depending on the source, but projections consistently show substantial growth potential.

Upturn SWOT Analysis

Strengths

  • Proprietary ProNeurau00ae drug delivery system
  • Potential for improved patient compliance with long-acting formulations
  • Focus on addressing the opioid crisis

Weaknesses

  • Dependence on a single product (Probuphine)
  • Financial instability and history of losses
  • Limited marketing and sales capabilities
  • Regulatory challenges related to implantable drug delivery

Opportunities

  • Expanding ProNeurau00ae platform to other therapeutic areas
  • Partnerships with larger pharmaceutical companies
  • Increased government funding and support for addiction treatment
  • Developing next-generation ProNeura implants

Threats

  • Competition from generic and branded buprenorphine products
  • Regulatory setbacks or changes in reimbursement policies
  • Product liability claims
  • Negative perception of opioid addiction treatment

Competitors and Market Share

competitor logo Key Competitors

  • OTCQX:INVV
  • OTCQX:BTNXF
  • ENDP

Competitive Landscape

Titan faces significant competition from larger pharmaceutical companies with established buprenorphine products. Their advantage is the long-acting implantable delivery, but challenges include cost and physician/patient acceptance.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been limited by the slow adoption of Probuphine and the company's financial constraints.

Future Projections: Future projections are highly uncertain and depend on successful commercialization of Probuphine and potential expansion of the ProNeurau00ae platform.

Recent Initiatives: Recent initiatives likely involve efforts to secure partnerships, expand market access for Probuphine, and develop new formulations using the ProNeurau00ae technology.

Summary

Titan Pharmaceuticals is a high-risk, high-reward biotech company with a proprietary drug delivery system, ProNeura. They are primarily focused on Probuphine, an implant for opioid addiction treatment. The company faces significant financial challenges and strong competition. Successful commercialization of Probuphine and expansion of the ProNeura platform are crucial for their future. Regulatory hurdles and market acceptance of implantable treatments pose ongoing risks.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings (10-K, 10-Q)
  • Company Website
  • Industry Reports
  • Analyst Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Financial data may be outdated. Invest at your own risk.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Titan Pharmaceuticals Inc

Exchange NASDAQ
Headquaters New York, NY, United States
IPO Launch date 1996-01-18
CEO -
Sector Healthcare
Industry Biotechnology
Full time employees -
Full time employees -

Titan Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development of therapeutics for the treatment of chronic diseases. Titan Pharmaceuticals, Inc. was founded in 1991 and is based in New York, New York.